Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Perry Elliott(St Bartholomew's Hospital), Sanjiv J. Shah(Northwestern University), Benjamin Li(Vanderbilt University), Marla B. Sultan(Pfizer (United States)), James E. Hoffman(Sylvester Comprehensive Cancer Center), Daniel J. Lenihan(Saint Francis Medical Center), Scott L. Hummel(VA Ann Arbor Healthcare System), Brian Drachman(Penn Presbyterian Medical Center), Stephen S. Gottlieb(University of Maryland, Baltimore), Ben Ebede(Pfizer (United States)), Balarama Gundapaneni(Pfizer (United States))
Circulation Heart Failure
December 20, 2021
10.1161/circheartfailure.120.008193
Cited by 198

Related Papers

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
|European Heart Journal|2008|2.7k